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High-risk transplantation-associated thrombotic microangiopathy (TMA) can present with multisystem
involvement and is associated with a poor outcome after hematopoietic stem cell transplantation (HSCT),
with < 20% 1-year survival. TMA may involve the intestinal vasculature and can present with bleeding and
ischemic colitis. There are no established pathologic criteria for the diagnosis of intestinal TMA (iTMA). The
goal of our study was to identify histologic features of iTMA and describe associated clinical features. We
evaluated endoscopic samples from 50 consecutive HSCT patients for 8 histopathologic signs of iTMA and
compared ﬁndings in 3 clinical groups based on the presence or absence of systemic high-risk TMA (hrTMA)
and the presence or absence of clinically staged intestinal graft-versus-host disease (iGVHD): TMA/iGVHD, no
TMA/iGVHD, and no TMA/no iGVHD. Thirty percent of the study subjects had a clinical diagnosis of systemic
hrTMA. On histology, loss of glands, intraluminal schistocytes, intraluminal ﬁbrin, intraluminal microthrombi,
endothelial cell separation, and total denudation of mucosa were signiﬁcantly more common in the hrTMA
group (P < .05). Intravascular thrombi were seen exclusively in patients with hrTMA. Mucosal hemorrhages
and endothelial cell swelling were more common in hrTMA patients but this difference did not reach sta-
tistical signiﬁcance. Patients with hrTMA were more likely to experience signiﬁcant abdominal pain and
gastrointestinal bleeding requiring multiple blood transfusions (P < .05). Our study shows that HSCT patients
with systemic hrTMA can have signiﬁcant bowel vascular injury that can be identiﬁed using deﬁned histo-
logic criteria. Recognition of these histologic signs in post-transplantation patients with signiﬁcant gastro-
intestinal symptoms may guide clinical decisions.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT)eassoci-
ated thrombotic microangiopathy (TMA) is a potentially life-
threatening pathologic process that signiﬁcantly contributes
to nonrelapse morbidity and mortality. The majority of re-
ports in the literature describe the effect of TMA on the
kidney, with important long-term consequences, including
end-stage renal disease [1-5]. However, little is known
about how TMA involves other organs, including theedgments on page 2000.
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ty for Blood and Marrow Transplantation.gastrointestinal (GI) tract [6]. Our recent prospective study
showed that severe life-threatening GI bleeding after HSCT
was observed only in patients with systemic high-risk TMA
(hrTMA) [7]. Although no other prospective studies are
available, previous retrospective studies have found signiﬁ-
cant relationships between endoscopic evidence of intestinal
TMA (iTMA) and extreme abdominal pain, GI bleeding, and
diarrhea [8-10]. Histologic signs of iTMA reported in the
literature include small blood vessel endothelial swelling
and denudation, visible schistocyteswithin the vessel lumen,
noninﬂammatory crypt degeneration, apoptosis and
detachment of epithelial cells, wedge-shaped segmental
injury, and/or interstitial edema with hemorrhage or frag-
mented red blood cells (RBC).
Our study objectives were to examine and delineate his-
tologic features of iTMA in children and young adults using
J. El-Bietar et al. / Biol Blood Marrow Transplant 21 (2015) 1994e2001 1995biopsy specimens and to associate the histologic ﬁndings
with clinical features of disease.
METHODS
Study Subjects
Three hundred thirty-eight allogeneic HSCT recipients underwent
transplantation at Cincinnati Children’s Hospital Medical Center between
June 2008 and December 2012. Those patients who underwent diagnostic
upper and lower GI endoscopies for any GI symptoms during the ﬁrst year
after HSCT were included in this study. The primary indication for endos-
copy was to rule out gut graft-versus-host disease (GVHD). Secondary in-
dications included investigation of ongoing infections or persistent GI
symptoms other than prolonged diarrhea. This researchwas performedwith
institutional review board approval. Demographic and transplantation data
collected included age, gender, diagnosis, stem cell source, HSCT condi-
tioning regimen, clinical stage of acute intestinal GVHD (iGVHD), the day
after HSCT when systemic hrTMA and iGVHD diagnoses were made, and the
day after HSCT when endoscopy was performed. The clinical symptoms for
all patients were acquired by rigorous review of the electronic medical re-
cord and included the presence or absence of bleeding, nausea or vomiting,
diarrhea, the need for 3 ormore blood product transfusions in 1week’s time,
documentation of pain requiring any narcotic medications, the presence of
hypertension, and coinfections. Clinical symptoms were captured and
documented 7 days before and 7 days after the date of GI endoscopy.
Patients received transfusion based on clinical indications (eg, signiﬁcant
bleeding) or if their hemoglobin and platelet count were <7 g/dL and <10 
109/L, respectively.
Deﬁnition of hrTMA and iGVHD
SystemichrTMAwasdiagnosedusingpublished risk stratiﬁcation criteria
that included evidence of terminal complement activation asmeasured by an
elevated soluble C5b-9 level above normal in the blood and proteinuria> 30
mg/dL, in addition to hematologic TMA markers (elevated lactate dehydro-
genase, haptoglobin belownormal, schistocytes, RBC andplatelet transfusion
dependence) at the time of TMA diagnosis [7,11-14]. The clinical diagnosis of
acute iGVHD was made using standard Glucksberg GVHD staging [15].
Maximum stage of iGVHD and the presence or absence of systemic hrTMA
were reported for all patients who received a diagnostic endoscopy. All study
subjects were divided into the following 3 clinical groups: (1) presence of
systemic hrTMA and iGVHD (TMA/iGVHD), (2) absence of systemic hrTMA
but presence of iGVHD (no TMA/iGVHD), or (3) absence of both systemic
hrTMA and iGVHD (no TMA/no iGVHD). This division was performed and
basedon established clinical criteria to gauge the incidence of iTMA inpatient
populations with or without systemic hrTMA [7,15].
Pathology Review- Deﬁnitions of Histologic Signs of iTMA and GVHD
The reviewing pathologist was blinded to the patients’ clinical history.
For patients having multiple endoscopic evaluations after HSCT, routine
hematoxylin and eosinestained slides from the ﬁrst diagnostic procedure
were used for this study. Each available study sample from the esophagus,
stomach, small intestine, and/or colon was evaluated for 8 histologic
markers previously reported as signs possibly associated with iTMA. These
included mucosal hemorrhage, loss of glands, intraluminal schistocytes,
intraluminal ﬁbrin, intraluminal microthrombi, endothelial cell swelling,
endothelial cell separation, and total denudation of mucosa. Each histologic
marker was listed as present or absent.
Mucosal hemorrhage was deﬁned by RBC extravasation from capillaries
into the lamina propria (LP). It is important to note that this can be differ-
entiated from procedure-related hemorrhage, which is typically diffuse in
distribution, located in the LP close to the surface epithelium, and contains
fresh, more intact RBCs. Loss of glands was deﬁned as an unequivocal count
of >50% reduction in the number of observed glands; GI biopsies should
contain approximately 50 to 60 glands, 20 to 30 glands, and 10 to 20 glands
per high-power ﬁeld ( 400) in the gastric fundus, gastric antrum, and
colon, respectively. Intraluminal schistocyteswere deﬁned by the presence of
fragmented and/or degenerated RBCs within the capillaries. The fragmented
RBCs had to represent >50% of total RBCs and in at least 50% of the capil-
laries within the LP. Intraluminal ﬁbrinwas deﬁned by the presence of ﬁbrin
material in at least 1 capillary in the LP and/or submucosa. Intraluminal
microthrombiwas deﬁned by the presence of thrombus, with and/or without
organization, occluding at least 1 capillary or small arteriole in the LP and/or
submucosa. Endothelial cell swelling was deﬁned by nuclear enlargement
more than 3 times wider than the normal width of endothelial cells in> 50%
of the capillaries in the LP. Endothelial cell separation was deﬁned by endo-
thelial cell detachment from the basement membrane in at least 1 capillary
in the LP and/or submucosa. Mucosal denudation was deﬁned by epithelial
denudation in at least 1 tissue fragment. Procedural artifacts were excluded.
Capillaries from normal controls were available for comparison.Histologic iGVHD features were identiﬁed and described as present or
absent based upon the degree of crypt apoptosis, apoptosis with the
development of crypt abscess, or crypt necrosis with loss of glands.
Statistical Analysis
Categorical and continuous data are described by frequencies (percent)
and median (range), respectively. Fisher’s exact or Wilcoxon rank-sum test
were used to determine the signiﬁcance of categorical and continuous data.
Statistical signiﬁcance was assessed by a P value of < .05. One patient
received an HSCT using stem cells from both bone marrow and cord blood.
This patient was considered as receiving only bone marrow for the purposes
of performing statistical analysis and calculating a P value for stem cell
source versus clinical groups.
RESULTS
Study Cohort Characteristics
Fifty consecutive allogeneic transplant recipients under-
going endoscopy met study criteria and were included into
analyses. The total number of patients who underwent
transplantation during this study period was 338. Patients
had biopsies of a median of 1 (range,1 to 4) anatomic site (eg,
esophagus, stomach, intestine, or colon), depending upon
the procedure (upper and/or lower endoscopy). There were a
total of 81 biopsy sites (4 to 18 slides per site) for our cohort
of 50 patients.
The demographic and transplantation characteristics for
study subjects are summarized in Table 1. Themajority of our
cohort was male (72%) with a median age of 6.6 years (range,
.6 to 28.7 years). Eighty percent of patients received HSCT for
nonmalignant disorders, including hematophagocytic lym-
phohistiocytoses, other primary immune deﬁciencies, and
bone marrow failure syndromes. The main stem cell source
was bone marrow (88%) from a fully matched unrelated
donor (50%). Forty-four percent and 56% of patients received
myeloablative and reduced-intensity conditioning regimens,
respectively. The majority (82%) of myeloablative regimens
did not include total body radiation. There was no statisti-
cally signiﬁcant difference in transplantation features be-
tween the 3 study groups.
Fifteen of 50 patients (30%) undergoing endoscopic
evaluation in our cohort were identiﬁed as having systemic
hrTMA (4.4%, or 15 of 338, of all patients undergoing trans-
plantation). The median time to TMA diagnosis was 39 days
after HSCT (range, 13 to 150). Seventy-two percent of pa-
tients undergoing endoscopy had a clinical diagnosis of
iGVHD at a median of 48 days after HSCT (range, 15 to 322).
The incidence of clinical stage 3 and 4 intestinal GVHD was
similar in the TMA/iGVHD and no TMA/iGVHD groups (80%
versus 76%). Endoscopy for all patients was done at the time
of GI symptom presentation, a median of 65 days (range, 26
to 341) after HSCT (Table 1).
Histologic Signs of iTMA and GVHD
Six of 8 histologic features previously described as
possibly associated with iTMA were more common in
patients with systemic hrTMA compared with those with
GVHD, reaching statistical signiﬁcance (P < .05). These his-
tologic features included loss of glands, endothelial cell
separation, total denudation of mucosa, intraluminal schis-
tocytes, intraluminal ﬁbrin, and intraluminal microthrombi
(Table 2). Mucosal hemorrhages were observed more
commonly in patients with systemic hrTMA (80%) compared
with the other groups (52.4% with no TMA/iGVHD and 36%
with no TMA/no iGVHD), but this difference did not reach
statistical signiﬁcance (P ¼ .057). Mucosal hemorrhages seen
in the setting of iTMA contained fragmented extravasated
and/or degenerated RBCs that were located at and/or close to
Table 2
Histologic Signs and Clinical Features
Feature TMA/
iGVHD
(n ¼ 15)
No TMA/
iGVHD
(n ¼ 21)
No TMA/No
iGVHD
(n ¼ 14)
P Value
Histologic sign
Mucosal
hemorrhages
12 (80%) 11 (52.4%) 5 (36%) .057
Loss of glands 11 (73.3%) 8 (38%) 0 (0%) <.0001
Intraluminal
schistocytes
10 (66.7%) 5 (23.8%) 3 (21.4%) .016
Intraluminal ﬁbrin 8 (53.3%) 2 (9.6%) 2 (14%) .008
Intraluminal
microthrombi
4 (26.5%) 0 (0%) 0 (0%) .01
Endothelial cell
swelling
13 (86.6%) 13 (61.9%) 7 (50%) .086
Endothelial cell
separation
8 (53.3%) 3 (14.3%) 1 (7%) .007
Total denudation of
areas of mucosa
7 (46.7%) 3 (14.3%) 0 (0%) .005
Clinical features
Bleeding 12 (80%) 5 (23.8%) 0 (0%) <.0001
Nausea/vomiting 10 (66.67%) 16 (76%) 9 (64.3%) .7346
Diarrhea 14 (93.3%) 19 (90.5%) 10 (71.4%) .2602
Transfusion for
blood loss
9 (60%) 2 (9.5%) 0 (0%) <.0001
Pain 14 (93.3%) 16 (76%) 6 (40%) .0124
Hypertension 6 (40%) 8 (36.1%) 8 (57.1%) .5139
Co-infections 8 (53.3%) 10 (47.6%) 7 (50%) 1.00
Total deaths 12 (80%) 9 (42.9%) 2 (14.3%) .0015
Nonrelapse deaths 10 (66.7%) 7 (33.3%) 2 (14.3%) .017
Table 1
Patient Demographics
Feature TMA/iGVHD No TMA/iGVHD No TMA/No iGVHD P Value
No. patients 15 21 14
Gender
Male 12 (80)% 16 (76.2%) 8 (57.1%) .3827
Female 3 (20%) 5 (23.8%) 6 (42.9%)
Age at HSCT, median (range), yr 10.3 (.6-19.4) 5.4 (.7-28.7) 5.9 (.6- 28.3) .6062
Diagnosis
Malignancy 2 (13.3%) 7 (33.3%) 1 (7.1%) .1746
Primary immune deﬁciency 10 (66.7%) 13 (61.9%) 9 (64.3%)
Bone marrow failure 3 (20%) 1 (4.8%) 4 (28.6%)
Stem cell source
Bone marrow 13 (86.7%) 18 (85.7%) 13 (92.9%) .6603
Peripheral blood 1 (6.7%) 3 (14.3%) 1 (7.1%)
Cord blood 1 (6.7%) 0 1*
Donor source
Related 3 (20%) 3 (14.3%) 4 (28.6%) .5478
Unrelated 12 (80%) 18 (85.7%) 10 (71.4%)
HLA match status
Fully matched 10 (66.7%) 12 (57.1%) 11 (78.6%) .484
Mismatched 5 (33.3%) 9 (42.9%) 3 (21.4%)
Conditioning regimen
Ablative (see below) 6 (40%) 9 (42.9%) 7 (50%) .8763
Reduced intensity (ﬂudarabine/melphalan) 9 (60%) 12 (57.1%) 7 (50%)
Ablative regimen
Chemo only (busulfan/cyclophoshamidey) 5 (83.3%) 7 (77.8%) 6 (85.7%) 1.00
TBI with cyclophosphamide 1 (16.7%) 2 (22.2%) 1 (14.3%)
Serotherapy
Anti-thymocyte globulin 6 (40%) 8 (77.8%) 7 (50%) .8705
Alemtuzumab 9 (60%) 9 (22.2%) 7 (50%)
GVHD prophylaxis
Calcineurin inhibitor (tacrolimus, cyclosporine) þ Steroid (methylprednisolone) 14 (93.3%) 14 (66.7%) 10 (71.4%) .4369
Calcineurin inhibitor þ mycophenolate 0 3 (14.3%) 0
Calcineurin inhibitor þ methotrexate 1 (6.7%) 5 (23.8%) 4 (28.6%)
Clinical stage 3-4 iGVHD 12 (80%) 16 (76.2%) 0 n/a
Day after HSCT of GI scope, median (range) þ63 (27-323) þ58 (26-254) þ87 (35-341) n/a
Day after HSCT of iGVHD diagnosis, median (range) þ53 (15-322) þ48 (18-251) n/a n/a
Day after HSCT of TMA diagnosis, median (range) þ39 (13-150) n/a n/a n/a
TBI indicated total body irradiation; n/a, not available.
* One patient received stem cells using both cord blood and bone marrow.
y These represent regimens that contain busulfan and cyclophosphamide. These regimens also included patients conditioned with busulfan, cyclophos-
phamide, and ﬂudarabine.
J. El-Bietar et al. / Biol Blood Marrow Transplant 21 (2015) 1994e20011996disrupted capillaries (a patchy distribution, Figure 1A). At
times, the capillaries were totally effaced and replaced by
hemorrhage. These areas also stained positive for hemosid-
erin deposits and hemosiderin-laden macrophages, indi-
cating old bleeding not directly associated with the
endoscopic procedure (Figure 1D). A representative picture
showing loss of glands and mucosal denudation is displayed
in Figure 2. The space between glands in patients with sys-
temic hrTMA was markedly widened and the intervening
stroma showed ﬁbroplasia and/or hyalinization. True
mucosal denudation was almost always associated with
regenerative epithelium and ﬁbrotic and/or hyalinized LP
stroma. These features, likely representative of a subacute or
chronic phase of ischemia, were also observed. Overt acute
ischemic colitis was not observed in any patient specimen.
Intraluminal schistocytes and endothelial cell separation,
more prevalent in the systemic hrTMA group, are displayed
in Figure 3. Intraluminal serum protein, which was a thinner,
paler, pink and translucent material, was clearly deﬁned
from true intraluminal ﬁbrin (Figure 3C,D). In iTMA cases,
ﬁbrin was also present in the space between the endothelial
cells and the basement membrane (Figure 3C,D). Intra-
luminal microthrombi were seen in 26.5% of patients with
systemic hrTMA, a feature seen exclusively in this group
(Figure 3E,F). Endothelial cell swelling was seen more
commonly in patients with hrTMA (86.6%) compared with
the other groups (61.9%with noTMA/iGVHD and 50%with no
Figure 1. Histologic samples showing mucosal hemorrhage (H&E, biopsies from 4 iTMA patients, A-C: colon, original magniﬁcation 100, 400, 600, respectively,
D: stomach, 400). (A) Patchy distribution of fragmented RBC extravasation located at and/or close to the disrupted capillaries in the lamina propria. (B-C) Capillaries
demonstrate fragmented RBC extravasation with partial (B, black arrow) and total (C, clear arrow) disruption of the wall. (D) Hemosiderin deposits (stained brown)
and hemosiderin-laden macrophages represent remote mucosal hemorrhage. Nikon Eclipse 80i, 10x/0.30, 40x/0.75, 60x/0.85, Diagnostic Instruments 14.2 Color
Mosaic, Spot software.
J. El-Bietar et al. / Biol Blood Marrow Transplant 21 (2015) 1994e2001 1997TMA/no iGVHD), but this difference also did not reach sta-
tistical signiﬁcance (P¼ .086) (Table 2). Patients without TMA
and without iGVHD did not have any evidence of mucosal
infarcts or total denudation of mucosa.
Eighty-three percent of all patients with a clinical
diagnosis of iGVHD (87% with hrTMA and 81% without
hrTMA) and 28.6% without a clinical diagnosis of iGVHDFigure 2. Histologic samples showing loss of glands and mucosal denudation (H&E, b
original magniﬁcation 200). (A-C) The surface epithelium is denuded. The lamina pr
partially replaced by regenerated epithelium (C, black arrows). Nikon Eclipse 80i, 10xwere found to have histologic signs of crypt apoptosis or
crypt necrosis with abscess formation consistent with gut
GVHD.
Clinical Features
Clinically signiﬁcant bleeding, deﬁned as the need for
more than 3 transfusions of blood products (RBC and/oriopsies from 3 iTMA patients, A-B: colon, original magniﬁcation 100, C: colon,
opria shows signiﬁcant (> 50%) gland loss, appears ﬁbrotic (B, asterisk), and is
/0.30, 20/0.75, Diagnostic Instruments 14.2 Color Mosaic, Spot software.
Figure 3. Histologic samples showing intraluminal schistocytes, ﬁbrin and microthrombi as well as endothelial cell swelling and separation. (A-B) Intraluminal
schistocytes (H&E, biopsies from 2 iTMA patients, colon, original magniﬁcation 400). Fragmented and degenerated RBCs (asterisk) are present within the capillaries.
(C-D) Intraluminal ﬁbrin (H&E, biopsies from 2 iTMA patients, C: esophagus, original magniﬁcation 400, D: colon, original magniﬁcation 400). Capillaries
demonstrate ﬁbrin debris in the lumen. Note the ﬁbrin is present in the space between separated endothelial cells (black arrows) and the basement membrane. (E-F)
Intraluminal microthrombi (H&E, biopsies from 2 iTMA patients, colon, original magniﬁcation 400). Capillaries are totally occluded by ﬁbrin (clear arrow). (G)
Endothelial cell swelling (H&E, biopsies from 2 iTMA patients, colon, original magniﬁcation 400). Capillaries are lined by endothelial cells (asterisk) with enlarged
nuclei > 3 times wider than the normal nuclei. (H) Endothelial cell separation (H&E, biopsies from 2 iTMA patients, colon, original magniﬁcation 400). The
endothelial cells are separated from the basement membrane (double arrow). Nikon Eclipse 80i, 40x/0.75, Diagnostic Instruments 14.2 Color Mosaic, Spot software.
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administration, was more commonly seen in patients with
systemic hrTMA (P < .05) (Table 2). There were no docu-
mented events of GI bleeding or the need for blood product
support in subjects without systemic hrTMA and without
iGVHD (no TMA/no iGVHD group). Fifty-three percent of
patients with TMA/iGVHD also had stool positive for
adenovirus, norovirus, herpes simplex virus, cytomegalo-
virus, Clostridium difﬁcile, and/or yeast species based on
analysis performed on stool. Forty-seven percent of patients
with no TMA/iGVHD had stool positive for adenovirus, nor-
ovirus, enterovirus, C. difﬁcile, and/or yeast species; and 50%
of patients with no TMA/no iGVHD had stool positive for
adenovirus, human herpes virus-6, Epstein Barr virus, and/or
C. difﬁcile. Overall survival was 20% (TMA/iGVHD), 57.1% (no
TMA/iGHVD), and 85.7% (no TMA/no iGVHD). Nonrelapse
mortality was higher (66.7%, P ¼ .017) in patients with TMA
compared with that in other clinical groups (33.3% in no
TMA/iGVHD and 14.3% in no TMA/no GVHD). There was no
statistically signiﬁcant difference in the incidence of diar-
rhea, nausea/vomiting, presence of hypertension, or coin-
ciding infections between these 3 groups.
DISCUSSION
To our knowledge, this is the largest retrospective analysis
examining 8 histologic signs of iTMA in pediatric and young
adult HSCT patients with GI symptoms who were pheno-
typed for systemic hrTMA using rigorous published diag-
nostic criteria. We have previously reported a TMA incidence
of 39% in 100 prospectively monitored patients. In this pre-
vious study, 26 of these 39 patients (67%) were found to
ﬁndings consistent with systemic hrTMA. Ten of 39 patients
with systemic hrTMA (25.6%) or 10% of all transplantation
patients were found to have signiﬁcant GI bleeding [7]. Inthis current study, 30% of our patients requiring endoscopic
evaluations had systemic hrTMA, constituting 4.4% of all
patients who underwent transplantation during this study
time. Future prospective studies will be required to examine
true incidences of systemic and intestinal TMA.
Our study identiﬁed 6 histological features of the gut bi-
opsies that were more common in children and young adults
with systemic hrTMA, and we believe these ﬁndings can be
used to help identify transplant recipients in whom TMA
contributes to their clinical symptoms. It is important to note
that GVHD and iTMA can occur together, and failure to
recognize and treat concomitant iTMA might contribute to
some cases of failure of GVHD therapy.
In our previous experience as well as reports in the
literature, patients with systemic hrTMA at the time of au-
topsy or small bowel surgical resection have been shown to
display marked angiopathic changes involving mesenteric
vessels [16]. In the current study, > 60% of patients with
systemic hrTMA had signiﬁcant evidence of intestinal
vascular endothelial injury, regardless of coincident clinical
gut GVHD. Themost signiﬁcant histologic markers associated
with iTMAwere endothelial cell separation from the vascular
wall, intraluminal schistocytes, intraluminal ﬁbrin, intra-
luminal microthrombi, loss of glands, and total denudation of
mucosa. Mucosal denudation and loss of glands are also
histologic features commonly interpreted as severe GVHD
but may likely also represent ischemic mucosal damage
caused by microangiopathy, especially in our patients with
systemic hrTMA. The other histologic signs of iTMA are
speciﬁc to the vasculature and have not been well described
in the context of GVHD. Some investigators have de-
emphasized the importance of thrombus formation in pa-
tients with TMA [14]. However, intravascular thrombosis was
exclusively seen in our patients with systemic hrTMA and
J. El-Bietar et al. / Biol Blood Marrow Transplant 21 (2015) 1994e2001 1999likely also reﬂects severe endothelial injury. Mucosal hem-
orrhages and endothelial cell swelling were also observed
more frequently in patients with systemic hrTMA, but this
difference did not reach statistical difference. All histologic
ﬁndings of iTMA must be evaluated in the context of other
ongoing symptoms on a case-by-case basis.
Severe abdominal pain due to ischemia and GI bleeding
were signiﬁcant clinical signs of iTMA and not necessarily
due to grade 3 and 4 iGVHD. Our patients with systemic
hrTMA experienced symptoms that clearly delineated them
from other patients who underwent endoscopy. Pain
requiring narcotics, bleeding, and the need for transfusion
were clearly more common among these patients. This has
been a recurrent observation seen in the limited prior pub-
lications reporting on patients with histologic and clinical
ﬁndings consistent with iTMA. Additionally, iTMA patients
with coincident iGVHD have been shown to recover from
voluminous diarrhea when treated with immunosuppres-
sants but may continue to have clinically signiﬁcant GI
blood loss, extremely debilitating pain, and transfusion
dependency due to ongoing microangiopathy in the bowel
[8-10,17,18]. Continued bleeding is likely due to ongoing
iTMA-induced ischemic colitis. These patients require treat-
ment strategies that address both TMA and GVHD.
Our study data support prior observations by Innamoto
et al. associating severe abdominal pain and intestinal
bleeding with iTMA. The authors reviewed 87 endoscopic
procedures done for chronic therapy-unresponsive diarrhea.
In that study, patients with iTMA presented with intestinal
bleeding and did not respond to immunosuppressive thera-
pies targeting iGVHD. Ninety-two percent (80 of 87) of
patients in the study cohort were found to have iTMA hall-
marked by histologic features similar to those used in our
study. Only 31% (27 of 87) and 12.6% (11 of 87) of patients
were found to have clinical and/or laboratory evidence sup-
porting iGVHD and systemic TMA diagnoses, respectively.
The authors concluded that iTMA is underdiagnosed and
might be more prevalent than iGVHD [8]. Other studies
analyzing both endoscopic and postmortem biopsies of HSCT
patients with GI symptoms have shown an equal prevalence
of iTMA in patient cohorts also found to have iGVHD. These
publications have illustrated the importance of coinfections
possibly contributing to both iTMA and iGVHD [9,10,17]. In
our cohort, a majority of patients (80% or 29 of 36) with a
clinical diagnosis of gut GVHD also had histologic evidence of
iGVHD. Additionally, about one half of patients in all 3 clinical
groups also had infectious pathogens identiﬁed in stool
samples. We screen all patients with diarrhea using a
comprehensive infectious disease panel. This close moni-
toring may explain the increased detection and incidence.
However, it is unlikely that these higher incidence rates of
infectionwere the primary trigger of ﬁndings in our study, as
the number of identiﬁed pathogens was similar in all 3
clinical groups. We did not see a signiﬁcant association of
infection and systemic TMA in our previously published
prospective study [7]. A clearer association of these factors
and iTMA may be answered in future studies.
Our data clearly show that intestinal vascular injury oc-
curs more often in patients with systemic hrTMA and may
not be solely from T cellemediated tissue injury due to
concurrent GVHD. Histologically proven iTMA has been
documented in autologous stem cell or solid-organ trans-
plantation where a concurrent diagnosis of GVHD is highly
unlikely [19,20]. Luft et al. showed that HSCT recipients with
TMAwho have a genetic predisposition for endothelial injuryoften develop refractory GVHD, with both complications
requiring aggressive intervention for an optimal outcome.
Such patients often have elevated markers, such as
angiopoietin-2, chemokine IL-8, hepatocyte growth factor,
and soluble thrombomodulin indicative of endothelial stress,
vulnerability and dysfunction [21,22]. Four of our patients
with systemic hrTMA still had clinically signiﬁcant GVHD at
the time of their death. Furthermore, 9 of these patients still
had clinically active TMA at the time of their death. It is
unclear whether iTMA or GVHD are completely separate
entities but our data indicate that patients with gut GVHD
and microvascular injury have inferior outcomes. Additional
prospective work should be performed to see if HSCT pa-
tients with systemic TMA develop iTMA in the absence of a
clinical or pathologic diagnosis of GVHD. Furthermore, these
studies could observe for whether or not such patients also
suffer the same poor prognosis.
Our data suggest that iTMA can contribute to signiﬁcant
morbidity and mortality in HSCT patients and should be
included in the differential diagnosis of GI pathology, espe-
cially in patients with intestinal bleeding and severe
abdominal pain without voluminous diarrhea typical for
iGVDH. Each intestinal biopsy should be carefully evaluated
not only for GVHD and infection but also for vascular endo-
thelial injury compatible with iTMA as described above.
However, assessment might be limited in some biopsy
specimens based on inadequate sampling of vessels because
of operator variability. Histological changes are typically
multifocal and may not be present in small representative
biopsies. Previous reports and our personal experience
examining autopsy and surgical bowel resection specimens
showed that iTMA may affect mesenteric arterioles, causing
ischemic bowel necrosis, and may not necessarily be visible
in smaller submucosal vessels [6,7,19,23,24]. It is important
to consider iTMA based on the highly suggestive clinical
symptoms of intestinal bleeding and severe pain in patients
with systemic hrTMA. These features may be present despite
a lack of histologic evidence. Additionally, histologic sections
that display denuded mucosa or loss of glands cannot be
solely attributed to GVHD, especially in patients with
symptoms of systemic hrTMA and bowel ischemia.
Recognition of iTMA may inﬂuence clinical management
decisions that improve HSCT outcome. Careful consider-
ation must be made for patients with symptoms consistent
with iGVHD, iTMA, and other ongoing HSCT complications.
Certain immunosuppressants, such as calcineurin inhibitors
given for GVHD, may worsen TMA. Previous groups have
showed that patients with iTMAwho were misdiagnosed as
having iGVHD had worse outcomes when calcineurin in-
hibitors were continued [8,10]. These agents have been
shown to contribute to the development of systemic TMA
and iTMA in both humans and animals after stem cell and
solid-organ transplantation [25-30]. Some studies have
shown that patients with iTMA had reversal of bleeding and
abdominal pain complaints when these agents were
stopped [8,10,17]. Fujino et al. were able to induce and then
successfully reverse histologic and clinical signs of iTMA in
rats exposed to tacrolimus [28]. The risk of exacerbating
GVHD as a result of lowering or even discontinuing certain
immunosuppressive agents underscores the need for
careful consideration of the risks and beneﬁts involved.
Yamada-Fujiwara et al. successfully addressed these con-
cerns by randomizing patients to different management
schema based on the presence of iTMA, GVHD, or both [17].
Patients with iTMA and GVHD had an increase in steroid
J. El-Bietar et al. / Biol Blood Marrow Transplant 21 (2015) 1994e20012000dose while calcineurin inhibitors were stopped. Despite
small numbers, the strategy and outcomes were positive.
Although controversial, total plasma exchange has also
been shown to be effective when implemented early, along
with the discontinuation of calcineurin inhibitors [16,31].
We recently showed that terminal complement blockade by
eculizumab may be useful therapy in HSCT patients with
TMA [19]. We have successfully treated iTMA and iGVHD
using combined therapies including the above strategies,
eculizumab as targeted therapy for TMA, and photopheresis
for iGVHD. However, further studies evaluating the effec-
tiveness of each strategy need to be performed.
In summary, we have shown that patients with systemic
hrTMA experience more signiﬁcant GI symptoms and have
histologic evidence of intestinal vascular injury that require
clinical intervention to reduce TMA-associated morbidity
and mortality. Histologic GI tissue evaluation should include
a careful examination of the small blood vessels of the gut
wall using histologic markers associated with iTMA. After
iTMA is identiﬁed, these patients will require closer moni-
toring and adjustment in treatment strategies based on
coinciding pathology, such as iGVHD or infections.
We acknowledge that our study is limited by retrospec-
tive review of patient samples and potential sampling errors.
Our study provides the incidence of systemic hrTMA with
signiﬁcant histologic and clinical evidence of iTMA in pa-
tients after HSCT. We were unable to show what proportion
of patients without systemic hrTMA develop isolated iTMA.
Furthermore, a large proportion of our pediatric patients
(64%) had primary immune deﬁciencies with a smaller pro-
portion (25%) receiving transplants for malignancy. It is un-
clear if our patients’ underlying primary disorders may have
contributed to histologic ﬁndings in the gut. However, we
prospectively observed a higher incidence of systemic TMA
in patients with nonmalignant disorders [7]. Additionally, it
is unclear how generalizable our ﬁndings may be to adult
HSCT recipients who underwent transplantation predomi-
nantly for malignant diseases. Our ﬁndings will require
additional validation with future prospective studies. How-
ever, our data deliver an important message of awareness
about the signiﬁcance of iTMA and provide a panel of
histologic features strongly associated with intestinal
microangiopathy.
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